Market Overview

Ascendiant Capital Maintains Strong Buy on Repros Therapeutics Inc., Lowers PT to $19.00

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for RPRX

DateFirmActionFromTo
Nov 2016Ladenburg ThalmannUpgradesNeutralBuy
Dec 2015Brean CapitalTerminatesBuy
Oct 2015Brean CapitalDowngradesBuyHold

View More Analyst Ratings for RPRX
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (RPRX)